 |
71 Diseases |  |
105 Trials |
|
105 Trials |  |
2830 News |  |
| «12...26272829303132333435363738» |
- Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer (clinicaltrials.gov) - Jun 24, 2015
P2, N=30, Recruiting, Sponsor: University of Southern California
Trial primary completion date: Aug 2015 --> Aug 2016
- |||| Halaven (eribulin mesylate) / Eisai
Enrollment open, Metastases: Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Jun 24, 2015
P2, N=112, Recruiting, Sponsor: Asan Medical Center
Trial primary completion date: Aug 2015 --> Aug 2016 Not yet recruiting --> Recruiting
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date: Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan. (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=590, Recruiting, Sponsor: Eisai Co., Ltd.
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2017 --> Feb 2018
- Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Surgery, Metastases: Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jun 11, 2015
P2, N=21, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2017 --> Feb 2018 Trial primary completion date: Jun 2015 --> Dec 2016
- || Halaven (eribulin mesylate) / Eisai
Biomarker, Trial primary completion date, IO biomarker: NeoEribulin: Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=200, Recruiting, Sponsor: SOLTI Breast Cancer Research Group
Trial primary completion date: Jun 2015 --> Dec 2016 Trial primary completion date: Jan 2015 --> Jun 2015
- |||| Halaven (eribulin mesylate) / Eisai
Trial completion, Trial primary completion date: Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer (clinicaltrials.gov) - Jun 8, 2015
P2, N=81, Completed, Sponsor: Eisai Inc.
Trial primary completion date: Jan 2015 --> Jun 2015 Active, not recruiting --> Completed | Trial primary completion date: May 2015 --> Oct 2014
- ||||| Halaven (eribulin mesylate) / Eisai
Enrollment closed, Metastases: Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes (clinicaltrials.gov) - Jun 6, 2015
P3, N=522, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Active, not recruiting --> Completed | Trial primary completion date: May 2015 --> Oct 2014 Recruiting --> Active, not recruiting
- Halaven (eribulin mesylate) / Eisai
Enrollment open, Trial primary completion date, Metastases: Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors (clinicaltrials.gov) - May 22, 2015
P=N/A, N=8, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2016 --> Dec 2016
- | Halaven (eribulin mesylate) / Eisai
Enrollment open: Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer (clinicaltrials.gov) - May 22, 2015
P2, N=30, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2016 --> Dec 2016 Not yet recruiting --> Recruiting
- | Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche
New P2 trial, Combination therapy, Metastases: PATRICIA: Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer (clinicaltrials.gov) - May 19, 2015
P2, N=138, Not yet recruiting, Sponsor: SOLTI Breast Cancer Research Group
- ||| Halaven (eribulin mesylate) / Eisai
New trial, Metastases: Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry (clinicaltrials.gov) - May 13, 2015
P=N/A, N=77, Active, not recruiting, Sponsor: Eisai Limited
- ||| Halaven (eribulin mesylate) / Eisai
New trial: Halaven Post-Marketing Surveillance (PMS) (clinicaltrials.gov) - May 12, 2015
P=N/A, N=3000, Recruiting, Sponsor: Eisai Korea Inc.
- Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Combination therapy, Metastases: Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination (clinicaltrials.gov) - May 1, 2015
P1, N=40, Active, not recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2015 --> Oct 2015
- || Xpovio (selinexor) / Karyopharm
Enrollment change, Combination therapy, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (clinicaltrials.gov) - Apr 28, 2015
P1, N=251, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Apr 2015 --> Oct 2015 N=51 --> 251
- ||| Xpovio (selinexor) / Karyopharm
New P1 trial, Combination therapy, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (clinicaltrials.gov) - Apr 25, 2015
P1, N=251, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Combination therapy, Metastases: A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients (clinicaltrials.gov) - Apr 23, 2015
P1, N=19, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
N=51 --> 251 Trial primary completion date: Jun 2015 --> Feb 2015
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment change, Metastases: Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer (clinicaltrials.gov) - Apr 23, 2015
P2, N=64, Active, not recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Jun 2015 --> Feb 2015 N=52 --> 64
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment change, Trial initiation date, Trial primary completion date, Metastases: A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer (clinicaltrials.gov) - Apr 23, 2015
P2, N=68, Completed, Sponsor: Eisai Inc.
N=52 --> 64 N=56 --> 68 | Initiation date: Nov 2010 --> Feb 2011 | Trial primary completion date: Dec 2013 --> Mar 2012
- ||| Halaven (eribulin mesylate) / Eisai
Trial completion, Phase classification, Enrollment change: Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S) (clinicaltrials.gov) - Apr 21, 2015
P=N/A, N=963, Completed, Sponsor: Eisai Co., Ltd.
N=56 --> 68 | Initiation date: Nov 2010 --> Feb 2011 | Trial primary completion date: Dec 2013 --> Mar 2012 Active, not recruiting --> Completed | Phase classification: P4 --> PN/A | N=500 --> 963
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Combination therapy: Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer (clinicaltrials.gov) - Apr 18, 2015
P2, N=77, Completed, Sponsor: Eisai Inc.
Active, not recruiting --> Completed | Phase classification: P4 --> PN/A | N=500 --> 963 Trial primary completion date: May 2014 --> Nov 2012
- ||| Xpovio (selinexor) / Karyopharm
New P1 trial, Combination therapy, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (clinicaltrials.gov) - Apr 17, 2015
P1, N=51, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- Halaven (eribulin mesylate) / Eisai
Enrollment closed, Trial primary completion date, Monotherapy, Metastases: MERIBEL: Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment (clinicaltrials.gov) - Apr 14, 2015
P2a, N=60, Active, not recruiting, Sponsor: Medica Scientia Innovation Research
Trial primary completion date: May 2014 --> Nov 2012 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Feb 2016
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment closed, Trial primary completion date: Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer (clinicaltrials.gov) - Apr 9, 2015
P2, N=80, Active, not recruiting, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Feb 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> May 2015
- | Halaven (eribulin mesylate) / Eisai
New P2 trial, Metastases: SAKK 25/14: Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer (clinicaltrials.gov) - Mar 31, 2015
P2, N=77, Not yet recruiting, Sponsor: Swiss Group for Clinical Cancer Research
- Halaven (eribulin mesylate) / Eisai, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial primary completion date, Metastases: A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer (clinicaltrials.gov) - Mar 31, 2015
P1/2, N=63, Active, not recruiting, Sponsor: howard safran
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> May 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Mar 2015
- | Halaven (eribulin mesylate) / Eisai, stenoparib (2X-121) / Allarity Therap, Oncoheroes
New P1/2 trial: Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers (clinicaltrials.gov) - Mar 24, 2015
P1/2, N=54, Not yet recruiting, Sponsor: The University of Texas Health Science Center at San Antonio
- Halaven (eribulin mesylate) / Eisai
Metastases: ReProLine: Retroprospective Real Life Observatory of Eribulin (clinicaltrials.gov) - Mar 19, 2015
P=N/A, N=753, Recruiting, Sponsor: Institut Cancerologie de l'Ouest
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment closed: Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy (clinicaltrials.gov) - Mar 19, 2015
P2, N=128, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Mar 2015 Recruiting --> Active, not recruiting
- Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer (clinicaltrials.gov) - Mar 7, 2015
P2, N=29, Recruiting, Sponsor: University of Washington
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2014 --> Nov 2015
- || Halaven (eribulin mesylate) / Eisai, Turalio (pexidartinib) / Daiichi Sankyo
Trial primary completion date, Metastases: Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Mar 7, 2015
P1/2, N=80, Recruiting, Sponsor: Hope Rugo, MD
Trial primary completion date: Nov 2014 --> Nov 2015 Trial primary completion date: Jan 2015 --> Jan 2016
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Combination therapy: Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies (clinicaltrials.gov) - Mar 7, 2015
P1/2, N=58, Recruiting, Sponsor: University of California, San Francisco
Trial primary completion date: Jan 2015 --> Jan 2016 Trial primary completion date: Sep 2015 --> Dec 2015
- ||| Halaven (eribulin mesylate) / Eisai
Clinical: Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan. (clinicaltrials.gov) - Feb 26, 2015
P=N/A, N=590, Recruiting, Sponsor: Eisai Co., Ltd.
- |||| Halaven (eribulin mesylate) / Eisai
Metastases: Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes (clinicaltrials.gov) - Jan 26, 2015
P3, N=440, Recruiting, Sponsor: Eisai Co., Ltd.
Trial primary completion date: Sep 2015 --> Dec 2015 Trial primary completion date: Jul 2015 --> Oct 2015
- || Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
New P3 trial, Combination therapy, Metastases: Detect V / CHEVENDO (Chemo vs. Endo) (clinicaltrials.gov) - Jan 26, 2015
P3, N=270, Not yet recruiting, Sponsor: Prof. W. Janni
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Combination therapy, Metastases: 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over. (clinicaltrials.gov) - Jan 26, 2015
P2, N=60, Recruiting, Sponsor: Katherine Tkaczuk
Trial primary completion date: Jul 2015 --> Oct 2015 Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: First Line Metastatic Breast Cancer Treatment (ESMERALDA) (clinicaltrials.gov) - Jan 15, 2015
P2, N=61, Active, not recruiting, Sponsor: ARCAGY/ GINECO GROUP
Not yet recruiting --> Recruiting Trial primary completion date: May 2015 --> Oct 2015
- Halaven (eribulin mesylate) / Eisai
Metastases: Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=8, Not yet recruiting, Sponsor: City of Hope Medical Center
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Trial initiation date, Metastases: A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer (clinicaltrials.gov) - Jan 15, 2015
P1, N=12, Completed, Sponsor: Eisai Co., Ltd.
Trial primary completion date: May 2015 --> Oct 2015 Active, not recruiting --> Completed | Initiation date: Oct 2012 --> Oct 2011
- Halaven (eribulin mesylate) / Eisai, Kisqali (ribociclib) / Novartis
Enrollment change, Circulating tumor cells, Tumor cell, Metastases: DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs). (clinicaltrials.gov) - Jan 8, 2015
P2, N=520, Recruiting, Sponsor: Prof. W. Janni
Active, not recruiting --> Completed | Initiation date: Oct 2012 --> Oct 2011 N=400 --> 520
- Halaven (eribulin mesylate) / Eisai
Enrollment change, Metastases: E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 7, 2015
P2, N=66, Completed, Sponsor: National Cancer Institute (NCI)
N=400 --> 520 N=48 --> 66
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer (clinicaltrials.gov) - Dec 19, 2014
P2, N=52, Active, not recruiting, Sponsor: Eisai Inc.
N=48 --> 66 Trial primary completion date: Sep 2014 --> Jun 2015
- Halaven (eribulin mesylate) / Eisai
Trial suspension: AOST1322: Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov) - Dec 19, 2014
P2, N=33, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2014 --> Jun 2015 Recruiting --> Suspended
- Halaven (eribulin mesylate) / Eisai
New P1 trial, Combination therapy: Phase I of Eribulin and Oral Irinotecan for Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Dec 19, 2014
P1, N=18, Not yet recruiting, Sponsor: Tom Badgett
- |||| Halaven (eribulin mesylate) / Eisai
Trial completion, Combination therapy: Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer (clinicaltrials.gov) - Dec 19, 2014
P2, N=77, Completed, Sponsor: Eisai Inc.
Recruiting --> Suspended Active, not recruiting --> Completed
- |||| Halaven (eribulin mesylate) / Eisai
Trial completion, Metastases: A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer (clinicaltrials.gov) - Dec 19, 2014
P2, N=56, Completed, Sponsor: Eisai Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Halaven (eribulin mesylate) / Eisai
Enrollment open, Trial initiation date, Surgery, Metastases: Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 17, 2014
P2, N=21, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Dec 2014
- Halaven (eribulin mesylate) / Eisai
Trial initiation date, Surgery, Metastases: Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 12, 2014
P2, N=21, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Dec 2014 Initiation date: Aug 2014 --> Apr 2015
- Halaven (eribulin mesylate) / Eisai
Trial primary completion date: Study of Eribulin in Children With Cancer to Determine Safety (clinicaltrials.gov) - Dec 6, 2014
P1, N=15, Recruiting, Sponsor: University of Oklahoma
Initiation date: Aug 2014 --> Apr 2015 Trial primary completion date: Jun 2015 --> Dec 2015
- | New P2 trial, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases: SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Nov 24, 2014
P2, N=460, Recruiting, Sponsor: UNICANCER
- Halaven (eribulin mesylate) / Eisai
Enrollment closed, Enrollment change, Combination therapy, Metastases: A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients (clinicaltrials.gov) - Nov 18, 2014
P1, N=19, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Jun 2015 --> Dec 2015 Recruiting --> Active, not recruiting | N=25 --> 19